Irlanda - inglés - HPRA (Health Products Regulatory Authority)

genetic s.p.a. - salmeterol; fluticasone propionate - pressurised inhalation, suspension - salmeterol and fluticasone

Kenia - inglés - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - salmeterol as salmeterol xinafoate ph. eur &… - inhalation powder - salmeterol as salmeterol xinafoate ph. eur 25… - salmeterol and fluticasone

Estados Unidos - inglés - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate and salmeterol inhalation powder is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. fluticasone propionate and salmeterol inhalation powder should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use fluticasone propionate and salmeterol inhalation powder is not indicated for the relief of acute bronchospasm. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. flutica

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

rowex ltd - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25 microgram/250 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate - pressurised inhalation suspension - 25 microgram

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

rex medical ltd - salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol - aerosol inhaler, metered dose - 0.025 mg/dose - active: salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol excipient: ethanol lecithin norflurane - asthma: meterol hfa inhaler is indicated in the regular treatment of asthma and prevention of bronchospasm in individuals aged 4 years and older with reversible obstructive airway disease, including those with symptoms of nocturnal asthma, when used in combination with a long-term asthma prevention medicine such as an inhaled corticosteroid. meterol hfa inhaler is not indicated for the treatment of acute asthma symptoms, for which a fast-acting inhaled bronchodilator (e.g. salbutamol) should be used. exercise-induced bronchospasm: meterol hfa inhaler is indicated in the regular prevention of exercise-induced bronchospasm in individuals aged 4 years and older. chronic obstructive pulmonary disease: meterol hfa inhaler is indicated in the regular maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol;   - powder for inhalation - 50 mcg/dose - active: salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol   excipient: lactose monohydrate - serevent is indicated for long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in adults and children who are receiving inhaled or oral corticosteroids. serevent should be used only as an adjunct to corticosteroids in the management of asthma. serevent should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

Malta - inglés - Malta Medicines Authority

cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - salmeterol - pressurised inhalation, suspension - salmeterol 25 µg - drugs for obstructive airway diseases

Malta - inglés - Malta Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - fluticasone propionate, salmeterol - inhalation powder - fluticasone propionate 100 µg salmeterol 50 µg - drugs for obstructive airway diseases

Malta - inglés - Malta Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - fluticasone propionate, salmeterol - inhalation powder - fluticasone propionate 250 µg salmeterol 50 µg - drugs for obstructive airway diseases